Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs altRX

Two GLP-1 providers, one scoreboard. We put CoreAge Rx and altRX head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 252 · Grade C

altRX

Visit altRX Full brief →

FDA warning letter, June 2026 — issued to Trinity HealthCare Supply, LLC dba altRx. See the FDA's warning letter database.

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 65 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.

That doesn't make altRX a bad call — it's best for readers comparing clinician-supported compounded care who can verify the full subscription term and the medical-disqualification exception. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
48
Supply Reliability
95
81
Transparency
90
72
Access Breadth
93
56
Clinical Oversight
92
82
Track Record
88
51
CoreAge RxBrief Score 94 · 65altRX

Price, coverage & the tracker

CoreAge RxaltRX
Brief Score94/100 (A)65/100 (C)
Semaglutide

From $79/mo

Annual offer: 12 months paid upfront, from $948.

Main site: from $99/mo; confirm the selected offer.

Full price details

From $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo

Confirm full subscription commitment

Semaglutide advertised at $89/month; minimum term, supplied quantity and full first payment unconfirmed.

Cancellation needs seventy-two hours before billing. Medical-disqualification refunds deduct services already used.

Full price details

Compounded semaglutide offered; complete selected-term quote unknown; advertises $89/month without the full initial charge or minimum commitment

Tirzepatide

From $129/mo

Annual offer: 12 months paid upfront, from $1,548.

Main site: from $149/mo; confirm the selected offer.

Full price details

From $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo

Confirm full subscription commitment

Tirzepatide advertised at $149/month; minimum term, supplied quantity and full first payment unconfirmed.

Cancellation needs seventy-two hours before billing. Filled medication and ordinary changes of mind are not refundable.

Full price details

Compounded tirzepatide offered; complete selected-term quote unknown; advertises $149/month without the full initial charge or minimum commitment

CoverageUS only; restrictions by state, confirmed at intakeMembership advertised in all fifty states and D.C.; prescribing authority, clinician and medication availability vary by location
Brand-name accessNot confirmedCurrent named GLP-1 offers are compounded; branded fulfillment was not established.
Oral / sublingualInjection onlyUnconfirmed
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.

altRX: Advertisements show $89 semaglutide/$149 tirzepatide per month; confirm the full initial charge and minimum term. Renewal cancellation requires seventy-two hours.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.